<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31490561</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2885</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of veterinary pharmacology and therapeutics</Title>
          <ISOAbbreviation>J Vet Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses.</ArticleTitle>
        <Pagination>
          <StartPage>617</StartPage>
          <EndPage>623</EndPage>
          <MedlinePgn>617-623</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvp.12808</ELocationID>
        <Abstract>
          <AbstractText>Hydroxyzine is a first-generation antihistamine and cetirizine, a second-generation antihistamine and active metabolite of hydroxyzine. Hydroxyzine is commonly used in performance horses and as such its use in closely regulated; however, there are no published studies suitable for establishing appropriate regulatory recommendations. In the current study, 12 exercised Thoroughbred research horses received a single oral administration of 500 mg of hydroxyzine. Blood and urine samples were collected prior to and up to 96 hr postdrug administration and concentrations of hydroxyzine and cetirizine determined using liquid chromatography-tandem mass spectrometry. A joint parent/metabolite population 2-compartment pharmacokinetic model with first-order absorption and elimination was utilized to describe the pharmacokinetics of both compounds. Serum hydroxyzine and cetirizine concentrations were above the limit of quantitation (0.1 ng/ml) of the assay at 96 hr (the last time point sampled). The terminal half-life was 7.41 and 7.13 hr for hydroxyzine and cetirizine, respectively. Findings from this study suggest that a prolonged withdrawal time should be observed if this compound is used in performance administered to performance horses and is classified as prohibited substance by the applicable regulatory body.</AbstractText>
          <CopyrightInformation>© 2019 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Knych</LastName>
            <ForeName>Heather K</ForeName>
            <Initials>HK</Initials>
            <Identifier Source="ORCID">0000-0002-8676-4970</Identifier>
            <AffiliationInfo>
              <Affiliation>K.L. Maddy Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, California.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weiner</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrics Consultant, Chapel Hill, North Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steinmetz</LastName>
            <ForeName>Stacy</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>K.L. Maddy Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flynn</LastName>
            <ForeName>Katherine</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>California Department of Food and Agriculture, Animal Health Branch, Sacramento, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKemie</LastName>
            <ForeName>Daniel S</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>K.L. Maddy Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, California.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Vet Pharmacol Ther</MedlineTA>
        <NlmUniqueID>7910920</NlmUniqueID>
        <ISSNLinking>0140-7783</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YO7261ME24</RegistryNumber>
          <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017332" MajorTopicYN="N">Cetirizine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006634" MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="N">Hydroxyzine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cetirizine</Keyword>
        <Keyword MajorTopicYN="N">hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetic modeling,metabolism</Keyword>
        <Keyword MajorTopicYN="N">racehorse</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31490561</ArticleId>
        <ArticleId IdType="doi">10.1111/jvp.12808</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Benedetti, M., Plisnier, M., Kaise, J., Maier, L., Baltes, E., Arendt, C., &amp; McCracken, N. (2001). Absorption, distribution, metabolism and excretion of [14C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. European Journal of Clinical Pharmacology, 57(8), 571-582. https://doi.org/10.1007/s002280100364</Citation>
        </Reference>
        <Reference>
          <Citation>Bizikova, P., Papich, M., &amp; Olivry, T. (2008). Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Veterinary Dermatology, 19(6), 348-357. https://doi.org/10.1111/j.1365-3164.2008.00697</Citation>
        </Reference>
        <Reference>
          <Citation>Church, M., &amp; Church, D. (2013). Pharmacology of antihistamines. Indian Journal of Dermatology, 58(3), 219-224. https://doi.org/10.4103/0019-5154.110832</Citation>
        </Reference>
        <Reference>
          <Citation>Juniper, E., Stahl, E., Dot, R., Simons, F., Allen, D., &amp; Howarth, P. (2005). Clinical outcomes and adverse effect monitoring in allergic rhinitis. The Journal of Allergy and Clinical Immunology, 115(3 Suppl 1), S390-S413. https://doi.org/10.1016/j.jaci.2004.12.014</Citation>
        </Reference>
        <Reference>
          <Citation>Knych, H. K., Arthur, R. M., Mitchell, M. M., Holser, I., Poppenga, R., Smith, L. L., … Gaskill, C. L. (2015). Pharmacokinetics and selected pharmacodynamics of cobalt following a single intravenous administration to horses. Drug Testing and Analysis, 7(7), 619-625. https://doi.org/10.1002/dta.1737</Citation>
        </Reference>
        <Reference>
          <Citation>Knych, H. K., Stanley, S. D., Arthur, R. M., &amp; McKemie, D. S. (2016). Elimination of cetirizine following administration of multiple doses to exercised Thoroughbred horses. Journal of Veterinary Pharmacology and Therapeutics, 39(5), https://doi.org/10.1111/jvp.12318</Citation>
        </Reference>
        <Reference>
          <Citation>Olsén, L., Bondesson, U., Broström, H., Tjälve, H., &amp; Ingvast-Larsson, C. (2008). Cetirizine in horses: Pharmacokinetics and pharmacodynamics following repeated oral administration. The Veterinary Journal, 177, 242-249. https://doi.org/10.1016/j.tvjl.2007.03.026</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, F. (2004). Advances in H1-antihistamines. New England Journal of Medicine, 351(21), 2203-2217.</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, F., &amp; Simons, K. (2011). Histamine and H1-antihistamines: Celebrating a century of progress. The Journal of Allergy and Clinical Immunology, 128(6), 1139-1150. https://doi.org/10.1016/j.jaci.2011.09.005</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, F., Simons, K., &amp; Frith, E. (1984). The pharmacokinetics and antihistaminic of the HI receptor antagonist hydroxyzine. The Journal of Allergy and Clinical Immunology, 73(1 Pt 1), 69-75.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamaoka, K., Nakagawa, T., &amp; Uno, T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics, 6(2), 165-175. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/671222. https://doi.org/10.1007/BF01117450</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
